News > COVID-19: China approves CSPC Pharma's RSV vaccine for clinical trials

COVID-19: China approves CSPC Pharma's RSV vaccine for clinical trials

RSV, which shows symptoms similar to a cold but can be fatal for young children and older adults, contributed to 17.6 per cent of one group of patients in Beijing dying within 60 days compared to 7.5 per cent for a group with influenza A virus infection. Like the RSV vaccine from competitor Moderna approved in the United States, CSPC's shot SYS6016 is based on synthetic messenger RNA (mRNA) technology that was popularised during the COVID-19 pandemic.